Rein Therapeutics Inc.
RNTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 3, 2025 | Loop Capital Markets | Kemp Dolliver | $6.00(+243%) | $1.75 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 1, 2026 |
| Brookline Capital | downgrade | Buy →Hold | Jan 21, 2026 |
| Brookline Capital | downgrade | Buy →Hold | Aug 19, 2025 |
Earnings History
Next report: Mar 3, 2027 · EPS est. $-0.13| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.10 | $-0.17 | — | — |
| May 15, 2026 | $-0.19 | $-0.49 | — | — |
| Mar 26, 2026 | $-1.09 | $-1.09 | — | — |
| Nov 14, 2025 | $-0.21 | $-0.24 | — | — |
| Aug 14, 2025 | $-0.28 | $-0.22 | — | — |
| Apr 7, 2025 | $-0.26 | $-0.14 | — | — |
| Dec 31, 2024 | $-1.89 | $-0.46 | — | — |
| Nov 14, 2024 | $-0.27 | $-0.25 | — | — |
News
AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, at 11:00 a.m. ET. A live webcast of the presentation may…
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will present at the following investor conferences in September.
Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026 AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indica…
Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) has earned an average rating of "Hold" from the four brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have issued a buy recommendation on the company.
AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.